Review of treatments that can ameliorate nonadherence in patients with schizophrenia

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 5, 2006, Pages 9-14

  Kane, John M ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE;

DRUG EFFECT; DRUG USE; HOSPITAL READMISSION; HUMAN; INJECTION SITE PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSOCIAL CARE; RELAPSE; REVIEW; SCHIZOPHRENIA;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAMUSCULAR; PATIENT READMISSION; PSYCHOTHERAPY; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 33744818896     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Hellewell JSE. Psychiatrists' perceptions of major treatment challenges [poster]. Presented at the 11th annual congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France
2. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-1315
3. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247
4. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of re-hospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-891
5. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41
6. Byerly M, Fisher R, Rush AJ, et al. A comparison of clinician vs electronic monitoring of antipsychotic adherence in schizophrenia [poster]. Presented at the 41st annual meeting of the American College of Neuropsychopharmacology; Dec 8-12, 2002; San Juan, Puerto Rico
7. Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653-1664
8. Kemp R, Kirov G, Everitt B, et al. Randomised controlled trial of compliance therapy: eighteen-month follow-up. Br J Psychiatry 1998;172:413-419
9. Mahmoud RA, Engelhart LM, Oster G, et al. Risperidone versus conventional antipsychotics: a prospective randomized, naturalistic effectiveness trial of outcomes in chronic schizophrenia [poster]. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; Dec 8-12, 1997; Waikoloa, Hawaii
10. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(suppl 16):14-17
11. Davis JM, Metalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773. Correction 1994;48:616
12. Hogarty GW, Schooler NR, Ulrich R, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 1979;36:1283-1294
13. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66
14. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003;64(suppl 16):34-40
15. Keith SJ, Kane JM, Turner M, et al. Guidelines for the use of long-acting injectable atypical antipsychotics [ACADEMIC HIGHLIGHTS]. J Clin Psychiatry 2004;65:120-131
16. Kane JM, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132
17. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(suppl 16):18-23
18. Lasser RA, Bossie CA, Gharabawi GM, et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005;8:427-438